27.71

0.40% -0.11

After Hours: 27.82 0.11 +0.40%

Hims Hers Health Inc (HIMS)

Overview News Price History Option Chain Financials Why HIMS Down? Discussions Forecast

Hims Hers Health Inc stock is traded at $27.71, with a volume of 6.60M. It is down -0.40% in the last 24 hours and down -13.84% over the past month. Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.

Previous Close:

$27.82

Open:

$27.73

24h Volume:

6.60M

Relative Volume:

0.44

Market Cap:

$6.47B

Revenue:

$2.35B

Net Income/Loss:

$128.37M

P/E Ratio:

53.07

EPS:

0.5221

Net Cash Flow:

$57.42M

1W Performance:

-3.92%

1M Performance:

-13.84%

6M Performance:

+68.45%

1Y Performance:

-42.40%

1-Day Range:

$27.38

$27.95

1-Week Range:

$27.38

$29.87

52-Week Range:

$13.74

$65.30

Hims Hers Health Inc Stock (HIMS) Company Profile

Name

Hims Hers Health Inc

Sector

Healthcare (1074)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

415-851-0195

Address

2269 CHESTNUT ST, SAN FRANCISCO

Employee

2,442

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

HIMS's Discussions on Twitter

Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HIMS Hims Hers Health Inc	27.71	7.43B	2.35B	128.37M	57.42M	0.5221
TAK Takeda Pharmaceutical Co Adr	18.45	57.90B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.36	42.89B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.60	43.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	75.81	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	487.61	22.35B	3.17B	1.29B	1.01B	27.09

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Initiated	JP Morgan	Overweight
Mar-10-26	Upgrade	BofA Securities	Underperform → Neutral
Mar-10-26	Upgrade	Citigroup	Sell → Neutral
Mar-09-26	Upgrade	Needham	Hold → Buy
Feb-24-26	Downgrade	BTIG Research	Buy → Neutral
Jan-12-26	Initiated	Evercore ISI	In-line
Dec-09-25	Initiated	Barclays	Overweight
Oct-21-25	Initiated	KeyBanc Capital Markets	Sector Weight
Jun-23-25	Downgrade	Needham	Buy → Hold
Jun-04-25	Reiterated	Needham	Buy
Apr-29-25	Downgrade	TD Cowen	Buy → Hold
Feb-18-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-10-25	Downgrade	Citigroup	Neutral → Sell
Jan-07-25	Initiated	BTIG Research	Buy
Dec-17-24	Initiated	Morgan Stanley	Overweight
Nov-14-24	Downgrade	BofA Securities	Buy → Underperform
Aug-22-24	Initiated	Needham	Buy
Aug-09-24	Downgrade	Imperial Capital	Outperform → In-line
May-22-24	Downgrade	Citigroup	Buy → Neutral
Apr-16-24	Downgrade	Jefferies	Buy → Hold
Apr-10-24	Initiated	Canaccord Genuity	Buy
Feb-28-24	Upgrade	Imperial Capital	In-line → Outperform
Feb-26-24	Initiated	Leerink Partners	Market Perform
Dec-07-23	Initiated	Imperial Capital	In-line
Jul-28-23	Initiated	TD Cowen	Outperform
Apr-11-23	Initiated	Robert W. Baird	Neutral
Feb-09-23	Upgrade	Jefferies	Hold → Buy
Nov-08-22	Upgrade	BofA Securities	Neutral → Buy
Nov-08-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Oct-17-22	Downgrade	Piper Sandler	Overweight → Neutral
Sep-07-22	Initiated	Truist	Hold
Jul-15-22	Initiated	SVB Leerink	Underperform
Apr-14-22	Initiated	Guggenheim	Buy
Apr-01-22	Resumed	Credit Suisse	Outperform
Mar-10-22	Initiated	Deutsche Bank	Hold
Dec-02-21	Initiated	Jefferies	Hold
Nov-11-21	Upgrade	Piper Sandler	Neutral → Overweight
Jul-06-21	Initiated	BofA Securities	Neutral
May-20-21	Upgrade	Credit Suisse	Neutral → Outperform
Apr-21-21	Initiated	Truist	Hold
Mar-09-21	Initiated	Credit Suisse	Neutral
Mar-02-21	Upgrade	Citigroup	Neutral → Buy
Feb-17-21	Initiated	Citigroup	Neutral
Feb-12-21	Initiated	Piper Sandler	Neutral
Feb-08-21	Initiated	Tigress Financial	Buy

View All

Hims Hers Health Inc Stock (HIMS) Latest News

12:00 PM

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, - globenewswire.com

12:00 PM

10:51 AM

Here's Why Teladoc's Integrated Care Business Deserves More Attention - Yahoo Finance

10:51 AM

Sep 06, 2026

2026-09-06 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Hims & Hers Health, Inc. (HIMS) and Encourages Investors to Learn More About the Investigation | NYSE:HIMS | Press Release - Stockhouse

Sep 06, 2026

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire

Sep 06, 2026

Sep 05, 2026

INVESTOR DEADLINE ALERT: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

Sep 05, 2026

HIMS Stock Kicks Off September In The Red: FDA’s GLP-1 Alert Steals The Spotlight From Australia Expansion - Stocktwits

Sep 05, 2026

Sep 04, 2026

Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc.HIMS - PR Newswire

Sep 04, 2026

Kaplan Fox Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026 - newmediawire.com

Sep 04, 2026

ROSEN, LEADING TRIAL COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - ACCESS Newswire

Sep 04, 2026

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Hims & Hers - globenewswire.com

Sep 04, 2026

Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (NYSE: HIMS) Who Suffered Losses to Contact the Firm Before November 2, 2026 - GlobeNewswire Inc.

Sep 04, 2026